date,title,source
Oct-23-18,Arvinas to Present at Two Protein Degradation Conferences,GlobeNewswire
Nov-20-18,Arvinas To Present at the 30th Annual Piper Jaffray Healthcare Conference,GlobeNewswire
Dec-07-18,"Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)",GlobeNewswire
Jan-04-19,Arvinas Receives Authorization to Proceed for its IND Application for PROTAC Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer,GlobeNewswire
Feb-01-19,"Protein Degradation: Finally, A Way To Treat 'Undruggable' Diseases?",Investor's Business Daily
Feb-07-19,Arvinas Announces Poster Presentation at ASCO 2019 Genitourinary Cancers Symposium,GlobeNewswire
Mar-25-19,"Arvinas Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of PROTAC Protein Degrader, ARV-110",GlobeNewswire
Mar-26-19,Arvinas Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update,GlobeNewswire
Apr-02-19,"Arvinas Strengthens Management Team with Internal Appointments of Andy Crew, Ph.D. as Chief Technology Officer and Ian Taylor, Ph.D. as Chief Scientific Officer",GlobeNewswire
